Amneal Pharmaceuticals

INOVIO (NASDAQ: INO) Stock Quote

Last Trade: US$0.55 -0.03 -5.18
Volume: 7,423,392
5-Day Change: -7.94%
YTD Change: -64.67%
Market Cap: US$144.800M

Latest News From INOVIO

PLYMOUTH MEETING, Pa. , June 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board... Read More
PLYMOUTH MEETING, Pa. , May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea , President and CEO, and Dr. Michael Sumner , CMO, will present at the 2023 Jefferies Healthcare Conference. 2023 Jefferies Healthcare... Read More
PLYMOUTH MEETING, Pa. , May 23, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company's product candidate for the treatment of Recurrent Respiratory... Read More
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatment New combined safety and immunological data showing tolerability and durable immune response presented at ABEA/COSM Announced positive data from Phase 1b trial with... Read More
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and has the potential to provide clinical benefit to adults with RRP PLYMOUTH MEETING, Pa. , May 8, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from... Read More
PLYMOUTH MEETING, Pa. , May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea , Ph.D., President and CEO, will present at the 2023 RBC Capital Markets Global Healthcare Conference. 2023 RBC Capital Markets Global... Read More
PLYMOUTH MEETING, Pa. , April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023 . Following the release, INOVIO will host a live conference... Read More
Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5 th PLYMOUTH MEETING, Pa. , April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for... Read More
European Commission to review and make a final decision, expected late May 2023 PLYMOUTH MEETING, Pa. , April 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Committee for Orphan Medicinal Products (COMP) has provided a... Read More
Oral presentation introduced new humoral and cellular response data indicating potential ability of INO-4201 to generate robust immune response and protect against Zaire ebolavirus PLYMOUTH MEETING, Pa. , April 17, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious... Read More
Immunological data from recently completed Phase 1b trial will be presented on April 16 th PLYMOUTH MEETING, Pa. , April 12, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for presentation for INO-4201 as... Read More
PLYMOUTH MEETING, Pa. , April 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to its newly hired Senior Vice President, Regulatory Affairs under its 2022 Inducement Plan (the "Inducement Plan"). The... Read More
PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea , Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference. Oppenheimer 33rd Annual Healthcare Conference... Read More
Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) Trial results did not meet the primary endpoint in the biomarker-selected population Trial results did achieve statistical significance in the all-participants population Highlights progress of promising product candidates: Positive preliminary data from Phase 1/2... Read More
10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgery Treatment with INO-3107 achieved statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year INO-3107 was well-tolerated and immunogenic, with efficacy and safety... Read More
PLYMOUTH MEETING, Pa. , Feb. 15, 2023 /PRNewswire/ -- INOVIO ( NASDAQ : INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter 2022 financial results will be released after the market close on March 1, 2023 . Following the release, INOVIO will host a live... Read More
PLYMOUTH MEETING, Pa. , Feb. 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). On February 2 nd , 2023 (the "Grant Date"), the... Read More
INO-4201 found to be well-tolerated in the trial Humoral responses were boosted in 100% (36 of 36) of treated participants PLYMOUTH MEETING, Pa. , Feb. 2, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive results from a Phase 1b... Read More
Cost-saving measures include 11% headcount reduction Annual savings expected to be approximately $4.3 million Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSIL PLYMOUTH MEETING, Pa. , Jan. 31, 2023 /PRNewswire/ -- INOVIO ( NASDAQ : INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people... Read More
C4 Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB